NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerGlobeNewsWire • Wednesday
NervGen Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • Monday
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord InjuryGlobeNewsWire • 11/12/26
NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury TranscriptSeeking Alpha • 09/30/26
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting AdjustmentsGlobeNewsWire • 09/25/26
NervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/13/26
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI StudyGlobeNewsWire • 05/26/26
NervGen Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/18/26
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial OfficerGlobeNewsWire • 04/27/26
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewsWire • 04/13/26
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic TetraplegiaGlobeNewsWire • 04/07/26
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/31/26
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical AffairsGlobeNewsWire • 03/04/26
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy SymposiumGlobeNewsWire • 02/11/26
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord InjuryGlobeNewsWire • 02/09/26